Peptide library / Bones & muscles / Abaloparatide
Abaloparatide
A synthetic analog of parathyroid hormone-related protein for osteoporosis.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Postmenopausal osteoporosisFDA approved
- Osteoporosis in menFDA approved
How it is thought to work
Abaloparatide activates the same receptor as teriparatide but with a signaling profile that favours bone building over bone breakdown.
What the evidence shows
The ACTIVE trial found fewer vertebral and non-vertebral fractures than placebo.
Safety and unknowns
Dizziness, a fast heartbeat and raised urinary calcium can occur.
Regulatory status
FDA-approved as Tymlos in 2017, with an indication for men added in 2022.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Bones & muscles
ACE-031
In clinical trialsA decoy receptor tested for muscle diseases, stopped after bleeding side effects.
Calcitonin
FDA-approvedA 32 amino acid hormone, usually from salmon, used for bone conditions and high calcium.
Vosoritide
FDA-approvedA C-type natriuretic peptide analog that increases growth in children with achondroplasia.
General information, not medical advice. Do not buy or inject unregulated peptides.